Table 1.

Study and demographic characteristics

Study	Substance	Doses	Subjects	Gender	Age (years)	Previous cannabis use	Previous hallucinogen use			Previous stimulant use			Previous MDMA use			No. of subjects with flashbacks		Interval between last session and end-of-study visit (days)		Interval between last session and follow-up (days)
NCT identifier	Name	mg	n	f/m	Mean (SD)	%	%	Mean (SD)	Range	%	Mean (SD)	Range	%	Mean (SD)	Range	n	%	Mean (SD)	Range	Mean (SD)	Range
NCT02308969	LSD	0.1	24	12/12	32.5 (11.1)	75.0	16.7	0.2 (0.5)	0–2	16.7	0.3 (0.7)	0–2	33.3	0.9 (1.6)	0–5	1	4.2	27.6 (24.1)	8–112	Lost to follow-up	Lost to follow-up
NCT03019822	LSD, MDMA, amph	0.1, 125, 40	27	14/13	28.0 (4.2)	85.2	11.1	0.1 (0.5)	0–2	44.4	0.9 (1.3)	0–4	29.6	0.8 (1.5)	0–5	2	7.4	87.6 (45.6)	35–193	1117.0	1082–1152
NCT03321136	LSD	0.025, 0.05, 0.1, 0.2	20	11/9	29.3 (6.3)	85.0	40.0	0.7 (1.0)	0–3	55.0	1.1. (1.3)	0–3	50.0	1.2 (1.6)	0–5	2	10.0	31.5 (21.8)	6–93	969.0	828–1110
NCT01878942	LSD	0.2	16	8/8	28.7 (6.4)	87.5	43.8	0.8 (1.0)	0–3	37.5	0.7 (1.1)	0–3	62.5	1.7 (2.0)	0–8	2	12.5	26.1 (9.8)	4–44	2644.5	2641–2648
NCT03604744	LSD, psilo	0.1 and 0.2, 15 and 30	31	17/14	36.1 (10.3)	90.3	45.2	1.3 (1.9)	0–8	41.9	0.9 (1.4)	0–5	41.9	1.1 (1.6)	0–5	4	12.9	40.5 (30.4)	6–140	382.5	101–589
NCT03912974	Psilo, escitalopram	25, 20	24	12/12	33.7 (9.7)	50.0	29.2	0.7 (1.5)	0–5	12.5	0.2 (0.7)	0–3	33.3	0.8 (1.4)	0–5	2	8.3	13.6 (12.0)	2–56	216.0	158–274
Total			142	74/68	31.7 (9.0)	78.9	30.3	0.7 (1.3)	0–8	34.5	0.7 (1.2)	0–5	40.1	1 (1.6)	0–8	13	9.2	39.8 (37.2)	2–193	951.9 (871.1)	101–2648

amph d-amphetamine, f female, m male, NCT National Clinical Trial number, psilo psilocybin, SD standard deviation